Início › Mieloma Múltiplo › Oregon
Ensaios clínicos de Mieloma Múltiplo em Oregon
20 estudos para Mieloma Múltiplo estão buscando participantes em locais em Oregon.
Cidades em Oregon
Texto oficial do estudo (Inglês)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Portland
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07391657A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Oregon Health And Science University, Portland
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07258511A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Willamette Valley Cancer Institute and Research Center, Eugene
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07518186Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06784167A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Willamette Valley Cancer Institute and Research Center /ID# 278721, Eugene
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Providence Health & Services, Portland
RecrutandoFase 2
Idades 12 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Oregon Health and Science University, Portland
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06297226A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Oregon Health and Science University /ID# 272282, Portland
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06953960A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Willamette Valley Cancer Institute and Research Center, Eugene
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07637578A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Providence Portland Medical Center, Portland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07075185Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Portland
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 14 de ago. de 2026 · NCT07764978Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Oregon Health & Science University, Portland
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 16 de jul. de 2026 · NCT05469893A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Willamette Valley Cancer Institute and Research Center /ID# 267088, Eugene
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de jul. de 2026 · NCT05650632Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- Providence Cancer Institute Clackamas Clinic, Clackamas
- e mais 7
RecrutandoFase 3
Todas as idades · Todos os sexos · Atualizado em 10 de jun. de 2026 · NCT05561387Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Oncology Associates of Oregon, Eugene
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de abr. de 2026 · NCT05972135Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 20 de abr. de 2026 · NCT03761108A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Oncology Associates of Oregon, Eugene
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 24 de mar. de 2026 · NCT04988555Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Local Institution - 0016, Portland
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 22 de jan. de 2026 · NCT06357754cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades 40 e acima · Todos os sexos · Atualizado em 20 de jan. de 2026 · NCT05366881Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.